An important part of treating your allergic asthma is staying informed and surrounding yourself with community and valuable support. Although your doctor is the best source of information about your condition and treatment with XOLAIR, below are a handful of tools and resources we think you may find useful:

Tools

Specialist Locator
Find an asthma specialist in your area and get tested for IgE.
Go now

Glossary
For a full list of Glossary terms, please click here

Asthma Control Test™(ACT)
Find out if your asthma is currently controlled. Go now

Resources

AsthmaMatters is a valuable resource for people living with allergic asthma. When you join the program, you’ll learn how to take a more active role in managing your condition. You’ll also receive:

  • A personalized Doctor Discussion Guide
  • A series of educational e-mails about allergic asthma and treatment
  • Helpful interactive tools and tips as well as links to other online resources

Visit Asthma Matters today


Xpansions is a free patient support program created for people on treatment with XOLAIR and their caregivers. As a member, you’ll receive a welcome mailing and have access to:

  • Xpansions.com: get helpful tips and tools, educational stories from other XOLAIR patients, and more
  • Our informative, quarterly newsletter sent straight to your home.
  • The XOLAIR Product Information Line: call 1-866-4XOLAIR (1-866-496-5247) to speak with a nurse educator who can help answer questions about your treatment with XOLAIR

Join the community designed specially for you. Sign up today


XOLAIR Access Solutions is a special team set up to help you and your doctor work through any issues with getting and starting XOLAIR. It provides assistance in 3 areas:

  1. 1. Coverage and reimbursement through a staff of dedicated experts
  2. 2. Patient assistance for people who are uninsured or financially challenged
  3. 3. Informational Resources, available to your doctor online or by phone, that provide more detail about being able to access XOLAIR

Learn more about XOLAIR Access Solutions. Go now

EXPECT XOLAIR Pregnancy Registry is a study that collects health information about women who are pregnant and have been treated with XOLAIR. It is used to provide patients and doctors with important information about the use of XOLAIR in pregnant women and their babies.

Pregnant or thinking of becoming pregnant?
If you've been treated with XOLAIR, you may be eligible to participate in the registry. Ask your doctor for more information, or simply visit www.XOLAIRpregnancyregistry.com.

WHO is XOLAIR for?
XOLAIR® (omalizumab) for subcutaneous use is an injectable, prescription medicine for patients ages 12 and older. It is for patients with moderate to severe persistent allergic asthma caused by year-round allergens in the air. A skin or blood test is done to see if you have allergic asthma. XOLAIR is for patients who are not controlled by asthma medicines called inhaled steroids.
XOLAIR helps reduce the number of asthma attacks in people with allergic asthma who still have asthma symptoms even though they are taking inhaled steroids.
Important Limitations of Use
XOLAIR has not been proven to work in other allergic conditions.
XOLAIR is not a rescue medicine and should not be used to treat sudden asthma attacks.
XOLAIR should not be used in children under 12 years of age.
IMPORTANT SAFETY INFORMATION
XOLAIR should always be injected in a doctor's office. You should read the Medication Guide before starting XOLAIR treatment and before each and every treatment.
A severe allergic reaction called anaphylaxis has happened in some patients after they received XOLAIR. Anaphylaxis is a life-threatening condition and can lead to death. Seek emergency medical treatment right away if symptoms occur. Signs and symptoms of anaphylaxis include:
wheezing, shortness of breath, cough, chest tightness, or trouble breathing
low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom"
flushing, itching, hives, or feeling warm
swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing
You should not receive XOLAIR if you have ever had an allergic reaction to a XOLAIR injection. Do not use XOLAIR if you are allergic to any of its ingredients.
In clinical studies 0.5% of patients receiving XOLAIR developed cancer, compared to 0.2% of patients receiving placebo (an injection with no active medicine).
Joint inflammation or pain, rash, fever, and swollen lymph nodes have been seen in patients taking XOLAIR. Talk to your doctor if you’ve experienced any of these signs and symptoms.
In patients >12 years of age, the most commonly observed side effects in asthma studies that had a >1% difference between XOLAIR and placebo were joint pain (8%), pain (general) ( 7%), leg pain (4%), tiredness (fatigue) (3%), dizziness (3%), fracture (2%), arm pain (2%), itching (2%), inflammation of the skin (2%), and earache (2%).
In asthma studies, the most common side effects in patients, who either needed to stop XOLAIR or needed medical attention, were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and sore throat (11%). These side effects were seen at the same rates in XOLAIR-treated patients as in patients in the control group who received placebo.
XOLAIR is not a rescue medicine and should not be used to treat sudden asthma attacks.
XOLAIR is not a substitute for the medicines you are already taking. Do not change or stop taking any of your other asthma medicines unless your doctor tells you to do so. You may not see an immediate improvement in your asthma when beginning XOLAIR therapy.
You are encouraged to report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch, or by calling 1-800-FDA-1088. You may also report any side effects at 1-866-4XOLAIR (1-866-496-5247).
Talk to your doctor for more information and if you have any questions about your treatment.
Please see full Prescribing Information and Medication Guide for additional important safety information.